In:
Annals of the New York Academy of Sciences, Wiley, Vol. 777, No. 1 ( 1996-01), p. 404-409
Abstract:
The pharmacological profile of HWA 285 favors its use in patients with both Alzheimer's disease (PDD) and/or vascular dementia (MID). Clinical trials showed clinically relevant, statistically significant efficacy in the domains of cognitive function, global function and activities of daily living (ADL) in both PDD and MID. HWA 285 had a prolonged symptomatic effect for at least 12 months, although therapeutic effects were seen already after the first 3 months of treatment. HWA 285 was very well tolerated for at least 1 year.
Type of Medium:
Online Resource
ISSN:
0077-8923
,
1749-6632
DOI:
10.1111/nyas.1996.777.issue-1
DOI:
10.1111/j.1749-6632.1996.tb34453.x
Language:
English
Publisher:
Wiley
Publication Date:
1996
detail.hit.zdb_id:
2834079-6
detail.hit.zdb_id:
211003-9
detail.hit.zdb_id:
2071584-5
SSG:
11
Bookmarklink